探讨釉质上皮型颅咽管瘤（ACP）患者血浆及脑脊液中热休克蛋白90α（Hsp90α）的表达及其临床意义。

选取自2014年7月至2015年10月清华大学玉泉医院神经外科手术治疗的患者，主要运用ELISA法，选取典型的良、恶性肿瘤作为参照物，测量纳入经病理证实的3组颅内肿瘤患者[ACP组14例、胶质母细胞瘤（GBM）组6例、脉络丛乳头状瘤（CPP）组6例]及颅骨缺损对照组（颅骨修补患者6例）血浆与脑脊液中Hsp90α的含量，通过统计学分析，研究其含量差异的意义。利用Western blot对血浆结果进行验证。

经量化分析后可知4组患者血浆和脑脊液中Hsp90α含量比较结果均为：GBM组>ACP组>CPP组=颅骨缺损对照组，说明ACP的侵袭性远高于传统良性肿瘤。经Western blot验证，血浆结果大致相同。

Hsp90α不仅能在所有患者的血浆、脑脊液中被检测出，在颅内肿瘤患者组中Hsp90α的含量高低与肿瘤的恶性程度相关。ACP患者血浆、脑脊液中Hsp90α含量高低，或从侧面证实其ACP具有一定侵袭性，或能辅助术后随访。

To investigate the heat shock protein 90α (Hsp90α) expression and its clinical significance in plasma and cerebral spinal fluid (CSF) of patients who suffer of adamantinomatous craniopharyngioma (ACP).

All patients come from Neurosurgery Department of Yuquan Hospital, Tsinghua University since July 2014 to October 2015. Hsp90α were detected from blood plasma and CSF in 14 patients with ACP, 6 patients with glioblastoma (GBM), 6 patients with choroid plexus papilloma (CPP) and 6 patients with cranioplasty (control) respectively by using method of ELISA. After that, Hsp90α values were analyzed, and evaluated the roles in differential diagnosis. The Western blot method was used for verification in plasma test.

Hsp90α levels in plasma and CSF of the patients enrolled are GBMs>ACPs>CPPs=Controls. We reveal that ACP is more aggressive than other benign tumors which belongs to WHO grade Ⅰ. These can be proved by plasma test of Western blot method.

Hsp90α was not only detected from blood plasma and CSF but also its level whichever in blood plasma and CSF are positively correlated with the malignancy of tumors, particularlly tumor invasion and metastasis. Hsp90α has certain significance in these patient’s blood plasma or CSF that ACP was confirmed to be invasive, or it could contribute to follow-up.